Pneumococcal Disease EU

CME

Pneumococcal Disease: Current Concepts for At-Risk Adults

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: August 22, 2024

Expiration: August 21, 2025

Activity

Progress
1 2
Course Completed

References

  1. Centers for Disease Control and Prevention. About pneumococcal vaccines. cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html. Accessed August 21, 2024.
  2. European Centre for Disease Prevention and Control. Factsheet about pneumococcal disease. 2023. ecdc.europa.eu/en/pneumococcal-disease/facts. Accessed August 21, 2024.
  3. Lansbury L, Lim B, McKeever TM, Lawrence H, Lim WS. Non-invasive pneumococcal pneumonia due to vaccine serotypes: A systematic review and meta-analysis. EClinicalMedicine. 2022;44:101271.
  4. European Centre for Disease Prevention and Control. Invasive pneumococcal disease - Annual Epidemiological Report for 2018. ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf Accessed August 21, 2024.
  5. Torres A, Cilloniz C, Blasi F, et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. Respir Med. 2018;137:6-13.
  6. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10:ofad192.
  7. Sabra A, Coulombel N, Duret S, et al. Burden of hospitalized pneumonia and pneumococcal infections in France during the 2013-2019 period: results from the EPHEBIA study. Médecine et Maladies Infectieuses Formation. 2022:1:S109-S110.
  8. Danis K, Varon E, Lepoutre A, et al. Factors associated with severe nonmeningitis invasive pneumococcal disease in adults in France. Open Forum Infect Dis. 2019;6:ofz510.
  9. Haute Autorité de Santé – HAS. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed),. has-sante.fr/upload/docs/evamed/CT-19827_APEXXNAR_PIC_INS_AvisDef_CT19827.pdf. Accessed August 21, 2024.
  10. Centre National de Référence des Pneumocoques - CNRP. 2022 epidemiology report. cnr-pneumo.com/docman/rapports/74-2022-epidemiologie-2021/file. Accessed August 21, 2024.
  11. Bahrs C, Kesselmeier M, Kolditz M, et al. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. Eur Respir J. 2022;59.
  12. Hansen K, Runow E, Torisson G, et al. Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016-2018-The ECAPS study. Front Public Health. 2023;11:1086648.
  13. Torres A, Menendez R, Espana PP, et al. The evolution and distribution of pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Spain using a serotype-specific urinary antigen detection test: The CAPA study, 2011-2018. Clin Infect Dis. 2021;73:1075-1085.
  14. Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax. 2020;75:38-49.
  15. Liapikou A, Konstantinidis A, Kossyvaki V, et al. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019. Hum Vaccin Immunother. 2022;18:2079923.
  16. Orsi A, Domnich A, Mosca S, et al. Prevalence of pneumococcal serotypes in community-acquired pneumonia among older adults in Italy: A multicenter cohort study. Microorganisms. 2022;11.
  17. Luong BL. Distribution of pneumococcal vaccines serotypes contained in vaccine in community-acquired pneumonia requiring hospitalisation in adults in France. Presented at: European Congress of Clinical Microbiology and Infectious Diseases; 2024. Abstr BE50407.
  18. de Miguel S, Domenech M, Gonzalez-Camacho F, et al. Nationwide trends of invasive pneumococcal disease in Spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era. Clin Infect Dis. 2021;73:e3778-e3787.
  19. Teixeira R, Kossyvaki V, Galvez P, Mendez C. Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review. Microorganisms. 2023;11.
  20. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One. 2017;12:e0177113.
  21. Hausdorff WP, Hanage WP. Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12:358-374.
  22. Noharet-Koenig R, Lasota K, Faivre P, Langevin E. Evolution of pneumococcal vaccine recommendations and criteria for decision making in 5 Western European countries and the United States. MDM Policy Pract. 2023;8:23814683231174432.
  23. Jansen K, Knirsch C, Anderson A. The role of vaccines in preventing bacterial antimicrobial resistance. nature.com/articles/nm.4465. Accessed August 21, 2024.
  24. European Medicines Agency. Prevnar 20. Summary of product characteristics. ema.europa.eu/en/documents/product-information/prevenar-20-epar-product-information_en.pdf. Accessed August 21, 2024.
  25. Hurley D, Griffin C, Young M, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2021;73:e1489-e1497.
  26. Sabharwal C, Sundaraiyer V, Peng Y, et al. Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease. Hum Vaccin Immunother. 2022;18:2126253.
  27. Danelian G, Burton L, Bayley T, et al. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England. Vaccine. 2024;42:3838-3850.
  28. Wyplosz B, Fernandes J, Sultan A, et al. Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study. Vaccine. 2022;40:4911-4921.
  29. Coalition for Life Course Immunisation. Pneumococcal vaccination atlas. pneumoniaatlas.org/#map-tabs|1. Accessed August 21, 2024.
  30. European Centre for Disease Prevention and Control. Pneumococcal disease: Recommended vaccinations. vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1. Accessed August 21, 2024.
  31. Duke JA, Avci FY. Emerging vaccine strategies against the incessant pneumococcal disease. NPJ Vaccines. 2023;8:122.